Abstract
The U.S. Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA) have issued a temporary rule that extends telemedicine flexibilities adopted during the COVID‐19 Public Health Emergency (PHE), an American Psychiatric Association's Psychiatric News Alert reported. The temporary rule was expected to go into effect on May 11, when the COVID‐19 PHE expires, and it extends the full set of telemedicine flexibilities adopted during the COVID‐19 PHE for six months (through Nov. 11, 2023). Additional flexibilities will extend to established patients until Nov. 11, 2024. “Access to evidence‐based treatment is a pillar of the HHS [U.S. Health and Human Services] Overdose Prevention Strategy,” said Miriam E. Delphin‐Rittmon, Ph.D., HHS assistant secretary for mental health and substance use and the leader of SAMHSA, in a May 9 press release issued by SAMHSA. “We strongly support policies that promote access to effective and safe treatment for opioid use disorder, including through telemedicine platforms, and ensuring continued access to necessary controlled medications past the COVID‐PHE.”
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
